MASAC Document 231 - Recommendation Regarding the Need for Updated Guidelines for Diagnosis and Management of von Willebrand Disease
Von Willebrand disease (VWD) is a common, mild to severe bleeding disorder for which the diagnosis and treatment remain less than optimal. There are hereditary and acquired causes of von Willebrand Factor (VWF) deficiency, including abnormalities in…
MASAC Document 232 - Recommendations on the Care and Treatment of Individuals with von Willebrand Disease
A von Willebrand disease (VWD) Summit organized by NHF focused on gaps in the care of individuals with VWD. A summary of the discussion highlighted the following issues: 1) Patients with VWD feel stigmatized and marginalized in terms of access to…
MASAC Document 274 - Recommendation on Administration of Inhibitor Bypassing Agents in the Home for Patients with Hemophilia and Inhibitors
Revisions: 271, 233 Background Persons with hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency) have frequent bleeding episodes that can be treated or prevented by infusion of the missing clotting factor (factor VIII…
MASAC Document 236 - Recommendations on Standardized Testing and Surveillance for Inhibitors in Patients with Hemophilia A and B
Revisions: 224; 203; 200; 193 Inhibitors are an important public health issue that result in increased morbidity and mortality and substantially increased financial burden for people with hemophilia. The CDC's Hemophilia Inhibitor Research Study…
MASAC Document 275 - MASAC Recommendations Regarding Physical Therapy Management for the Care of Persons with Bleeding Disorders
Thanks to the contributors of this document:Lora Joyner, Chair Amanda Kilgore, Vice ChairRyan Rushton, Cindy Bailey, Bruno Steiner, Kim Baumann, Pattye Tobase, and PTWG 2022 members This material is provided for your general information only.…
MASAC Document 281 - MASAC Recommendations on Screening for Development of Hepatocellular Cancer in Persons with Hepatitis B and C
Replaces: 239, 270Statement of ProblemPatients with viral hepatitis due to hepatitis B (HBV) and C (HCV) infection have been shown to have a significantly increased risk of end-stage liver disease, hepatocellular cancer (HCC), and death due to these…
MASAC Document 267 - MASAC Recommendation Concerning Prophylaxis for Hemophilia A and B with and without Inhibitors
Revisions: 170; 179; 241 In view of the demonstrated benefits of prophylaxis begun at a young age in persons with hemophilia A or B (PwH), MASAC recommends that prophylaxis be considered standard of care therapy for individuals with severe…
MASAC Document 242 - Recommendations Regarding Doses of Clotting Factor Concentrate in the Home
Individuals with hemophilia and other bleeding disorders require prompt treatment of bleeding episodes. Bleeding episodes can occur at any time and are often unpredictable; bleeding events may be spontaneous or may occur after minor or major injury…
MASAC Document 243 - Recommendation on SIPPET (Survey of Inhibitors in Plasma-Product-Exposed Toddlers): Results and Recommendations for Treatment Products for Previously Untreated Patients with Hemophilia A
The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) on June 17, 2016, and adopted by the NHF Board of Directors on June 28, 2016. The development of inhibitors (neutralizing antibodies to…
MASAC Document 266 - MASAC Recommendations Regarding the Treatment of von Willebrand Disease
Revisions: 244; 186; 173; 196 von Willebrand disease (VWD) is the most common inherited bleeding disorder and affects males and females equally in up to 1% of the general population. (1,2) VWD is associated with mucous membrane bleeding,…